DLL3 is expressed by neuroendocrine cancers, including prostate cancer! They plan to start a phase 1 trial by the end of 2024 (on lung cancer, but it’s worth to keep an eye on it).
“ABD-147 is a next-generation precision radiopharmaceutical biologic therapy designed to deliver Actinium-225 (225Ac) to solid tumors expressing DLL3, a protein found on the surface of neuroendocrine tumors, but rarely expressed on the surface of normal cells or tissues.”